
Pfizer Inc.
Pfizer Inc. is a United States-based company in the Healthcare sector with a market capitalisation of $168.6B. Its FinScore is 65/100; its highest-scoring layer is Momentum (90) and its lowest is Growth (46). The shares trade at 38.9x trailing earnings and are up 17% year to date.
Share price performance
About Pfizer Inc.
www.pfizer.comPfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- HQ
- United States
- Fiscal year-end
- December
- Trading currency
- USD
- Reporting currency
- USD
- Fundamentals updated
- 24 days ago
- Market cap
- $168.6B
- Shares outstanding
- 5.7B
- P/E (TTM)
- 38.9x
- Dividend yield (TTM)
- 5.81%
- Beta (issuer)
- 0.28
- Revenue (latest FY)
- $62.6B
Revenue breakdown
- Biopharma Segment97.8%$61.2B
- Segment Reporting, Reconciling Item, Corporate Nonsegment2.2%$1.4B
FinScore
As of 2026-10-19Snapshot
Ownership
As of 2026-06-30Sign up or log in to see Analysis
Analysis for Pfizer Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Financials
Financials for Pfizer Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Estimates
Estimates for Pfizer Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Peers
Peers for Pfizer Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Valuation
Valuation for Pfizer Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see News
News for Pfizer Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.